KIT inhibition by imatinib in patients with severe refractory asthma

New England Journal of Medicine

Volumn 376, Issue 20, 2017, Pages 1911-1920

  Cahill, Katherine N ^a   Katz, Howard R ^a   Cui, Jing ^a   Lai, Juying ^a   Kazani, Shamsah ^b   Crosby Thompson, Allison ^a   Garofalo, Denise ^a   Castro, Mario ^c   Jarjour, Nizar ^d   DiMango, Emily ^e   Erzurum, Serpil ^f   Trevor, Jennifer L ^g   Shenoy, Kartik ^h   Chinchilli, Vernon M ⁱ   Wechsler, Michael E ^j   Laidlaw, Tanya M ^a   Boyce, Joshua A ^a   Israel, Elliot ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e Department of Medicine   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h TEMPLE UNIVERSITY   (United States)

ⁱ PENN STATE COLLEGE OF MEDICINE   (United States)

^j DEPARTMENT OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; IMATINIB; LEUKOTRIENE RECEPTOR AFFECTING AGENT; METHACHOLINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OMALIZUMAB; PLACEBO; STEM CELL FACTOR RECEPTOR; METHACHOLINE CHLORIDE; PROTEIN KINASE INHIBITOR; TRYPTASE;

ADULT; ARTICLE; ASTHMA; BRONCHOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MAST CELL; MUSCLE CRAMP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; BLOOD; BRONCHIAL HYPERREACTIVITY; CELL COUNT; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; INHALATION TEST; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; QUALITY OF LIFE; SECRETION (PROCESS);

ADULT; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; CELL COUNT; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMATINIB MESYLATE; MALE; MAST CELLS; METHACHOLINE CHLORIDE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; TRYPTASES;

EID: 85019781627     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1613125     Document Type: Article

References (37)

1. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149-60.
2. Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007;119:1337-48.
3. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000;106:1033-42.
4. Limb SL, Brown KC, Wood RA, et al. Irreversible lung function deficits in young adults with a history of childhood asthma. J Allergy Clin Immunol 2005;116:1213-9.
5. Porsbjerg C, Rasmussen L, Nolte H, Backer V. Association of airway hyperresponsiveness with reduced quality of life in patients with moderate to severe asthma. Ann Allergy Asthma Immunol 2007;98:44-50.
6. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999;159:1043-51.
7. Ward C, Johns DP, Bish R, et al. Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma. Am J Respir Crit Care Med 2001;164:1718-21.
8. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006;117:1277-84.
9. Siddiqui S, Mistry V, Doe C, et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol 2008;122:335-41.
10. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-705.
11. Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol 2006;20:21-39.
12. Makowska JS, Cieslak M, Kowalski ML. Stem cell factor and its soluble receptor (c-kit) in serum of asthmatic patients-correlation with disease severity. BMC Pulm Med 2009;9:27.
13. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90:4947-52.
14. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
15. Cerny-Reiterer S, Rabenhorst A, Stefanzl G, et al. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. Oncotarget 2015;6:3071-84.
16. Farha S, Dweik R, Rahaghi F, et al. Imatinib in pulmonary arterial hypertension: c-Kit inhibition. Pulm Circ 2014;4:452-5.
17. Kraft M, Martin RJ, Lazarus SC, et al. Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. Chest 2003;124:42-50.
18. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
19. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7.
20. Prescribing information: Gleevec. Novartis, September 2016 (https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/gleevec-tabs.pdf).
21. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-8.
22. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998;114:998-1007.
23. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
24. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts LJ II. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995;104:937-40.
25. Morrow JD, Minton TA. Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry. J Chromatogr 1993;612:179-85.
26. Kim DC, Hsu FI, Barrett NA, et al. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol 2006;176:4440-8.
27. Aysola RS, Hoffman EA, Gierada D, et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008;134:1183-91.
28. Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol 2000;105:752-9.
29. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma - summary report 2007. J Allergy Clin Immunol 2007;120:Suppl:S94-138.
30. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
31. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
32. Yu M, Eckart MR, Morgan AA, et al. Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma. J Clin Invest 2011;121:3133-43.
33. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8.
34. Boyd A, Ribeiro JM, Nutman TB. Human CD117 (cKit)+ innate lymphoid cells have a discrete transcriptional profile at homeostasis and are expanded during filarial infection. PLoS One 2014;9(9):e108649.
35. Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol 2016;17:765-74.
36. McKenzie AN, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity 2014;41:366-74.
37. Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med 2006;6:409-21.